## Terns Pharmaceuticals (TERN) — filings-first deep dive (SEC disclosures) ### Quick navigation (pick your angle) 1) **What the company is (and what it’s becoming)** → *Business model & strategy* 2) **Pipeline + catalyst calendar** → *Programs, trials, what to watch* 3) **Financial runway & burn** → *Cash, cash flow, operating expense mix* 4) **Capital structure & dilution history** → *Offerings, share count, ATM capacity* 5) **Governance & incentives** → *Exec comp signals* 6) **Risk radar (filings-only)** → *China exposure, manufacturing, clinical/regulatory* --- ## 1) What Terns is (and what it’s becoming) Terns describes itself as a **clinical-stage biopharmaceutical company** with a **portfolio of small-molecule candidates** spanning **oncology and obesity**. ["clinical-stage biopharmaceutical company"](0000950170-25-042695|0) A key “tell” in recent disclosures is how management frames the company’s future: it emphasizes **no approved products** and **no product revenue**, with progress and valuation hinging on clinical execution and capital access. ["no products approved"](0000950170-25-042695|0) ["have not generated any revenue"](0000950170-25-042695|0) --- ## 2) Pipeline + catalysts (from the 10‑K and recent 8‑K exhibits) ### 2.1 Pipeline snapshot (as disclosed) The FY2024 10‑K explicitly calls out these as the “most advanced” internally discovered programs: **TERN‑701, TERN‑601, TERN‑501**, plus **TERN‑800 series** discovery efforts. ["most advanced product candidates"](0000950170-25-042695|0) **What each program is (company language):** - **TERN‑701 (CML):** oral, allosteric **BCR‑ABL** TKI targeting the **ABL myristoyl pocket**; Phase 1 CARDINAL discussed; further data expected **Q4 2025** (per 10‑K). ["TERN-701 is our proprietary, oral"](0000950170-25-042695|0) ["Additional safety and efficacy data"](0000950170-25-042695|0) - **TERN‑601 (obesity):** oral, once-daily **GLP‑1 receptor agonist**; Phase 2 **FALCON** initiated (first patient enrolled March 2025), **12-week data expected Q4 2025**. ["TERN-601 is our small-molecule GLP-1 receptor agonist"](0000950170-25-042695|0) ["12-week data are expected"](0000950170-25-042695|0) - **TERN‑501 (legacy metabolic):** **THR‑β agonist**; company says it decided to **limit spend for MASH** after Phase 2a DUET top-line data, and is evaluating other opportunities. ["limit spend"](0000950170-25-042695|0) ### 2.2 “Near-term” oncology narrative: 2026 milestones for TERN‑701 In the Jan 2026 8‑K Exhibit 99.1 (JPM conference update), Terns lays out a concrete milestone chain for **TERN‑701**: - **Pivotal dose selection** mid‑2026 ["Selection of pivotal dose"](0001193125-26-008907|1) - **End‑of‑Phase‑2 FDA interaction** mid‑2026 ["End of Phase 2"](0001193125-26-008907|1) - **Updated/expanded CARDINAL data** by **2H26** ["updated and expanded CARDINAL data"](0001193125-26-008907|1) - **Initiate first 2L+ pivotal trial** late 2026 / early 2027 ["initiation of 2L+ pivotal trial"](0001193125-26-008907|1) It also states **FDA Fast Track designation** for CML in **Q4 2025**. ["Fast Track designation"](0001193125-26-008907|1) ### 2.3 “Interactive” catalyst checklist (how to use this) If you’re tracking TERN as a catalyst-driven name, you can treat these as *gates*: **Gate A — Dose & regulatory alignment (mid‑2026)** - Dose selection and EOP2 meeting matter because they convert “promising Phase 1/2” into a pivotal path. ["Selection of pivotal dose"](0001193125-26-008907|1) ["End of Phase 2"](0001193125-26-008907|1) **Gate B — Data durability and line-of-therapy expansion (2H26)** - Updated/expanded CARDINAL data is the proof point for both efficacy durability and safety profile scaling. ["updated and expanded CARDINAL data"](0001193125-26-008907|1) **Gate C — Pivotal trial start (late 2026/early 2027)** - Initiation is where spend profile can step up (trial footprint, manufacturing, site ramp). ["Initiation of first pivotal trial"](0001193125-26-008907|1) --- ## 3) Financial runway & burn (grounded in 10‑K + latest 10‑Q pulled) ### 3.1 Balance sheet: liquidity position (FY2024 vs Q3’25) **Condensed balance sheet (USD millions; filings scale is thousands, rescaled)** | Metric | FY2024 (Dec 31, 2024) | Q3’25 (Sep 30, 2025) | |---|---:|---:| | Cash & cash equivalents | $161.439 ["Cash and cash equivalents"](0000950170-25-042695|0) | $150.698 ["Cash and cash equivalents"](0001193125-25-274367|0) | | Marketable securities | $196.725 ["Marketable securities"](0000950170-25-042695|0) | $144.937 ["Marketable securities"](0001193125-25-274367|0) | | Total assets | $363.929 ["Total assets"](0000950170-25-042695|0) | $301.651 ["Total assets"](0001193125-25-274367|0) | **Interpretation:** Between FY2024 and Q3’25, total liquidity (cash + marketable securities) decreased, consistent with a development-stage company funding R&D primarily from its cash stack. ["Net cash used in operating activities"](0001193125-25-274367|0) ### 3.2 Operating burn & expense structure **Cash burn proxy = net cash used in operating activities** | Period | Net cash used in operating activities (USD millions) | |---|---:| | FY2024 | $70.016 ["Net cash used in operating activities"](0000950170-25-042695|0) | | FY2023 | $67.390 ["Net cash used in operating activities"](0000950170-25-042695|0) | | 9M 2025 | $63.093 ["Net cash used in operating activities"](0001193125-25-274367|0) | | 9M 2024 | $55.432 ["Net cash used in operating activities"](0001193125-25-274367|0) | **Operating P&L (FY2024 vs FY2023; USD millions)** | Metric | FY2024 | FY2023 | |---|---:|---:| | R&D expense | $70.112 ["Research and development"](0000950170-25-042695|0) | $63.497 ["Research and development"](0000950170-25-042695|0) | | G&A expense | $31.759 ["General and administrative"](0000950170-25-042695|0) | $39.061 ["General and administrative"](0000950170-25-042695|0) | | Net loss | $(88.853) ["Net loss"](0000950170-25-042695|0) | $(90.210) ["Net loss"](0000950170-25-042695|0) | **What stands out:** - Terns’ cost base is dominated by **R&D**, as expected, but **G&A fell** year-over-year in FY2024, with the 10‑K attributing the decrease primarily to lower personnel-related expenses vs 2023 leadership transition costs. ["decrease in general and administrative"](0000950170-25-042695|0) - Despite large net losses, **interest income is meaningful** (a function of the cash/investment base). ["Interest income"](0000950170-25-042695|0) ### 3.3 Runway: management guidance vs observed burn Management states it expects **existing capital resources to fund planned operating expenses into 2028** (10‑K). ["fund our planned operating expenses into 2028"](0000950170-25-042695|0) Separately, the Jan 2026 8‑K Exhibit 99.1 gives a dramatically updated post-financing view: **year‑end 2025 unaudited cash, cash equivalents and marketable securities of ~ $1.0B**, runway **into 2031** (company expectation). ["approximately $1.0 billion"](0001193125-26-008907|1) ["runway into 2031"](0001193125-26-008907|1) **How to sanity-check (interactive prompt):** - If you assume FY2024 operating cash use of about **$70M/year** continues, $1.0B could theoretically last well beyond 2031; but pivotal oncology trials can change the burn slope materially. The filings themselves flag that operating plans may change and additional funding may be needed sooner depending on factors. ["operating plans may change"](0000950170-25-042695|0) --- ## 4) Capital structure & dilution: what the disclosures say ### 4.1 Share count anchor points (from financial statements) - Shares **issued and outstanding** at **Dec 31, 2024:** **87,126,583**. ["87,126,583 shares issued and outstanding"](0000950170-25-042695|0) - Shares **issued and outstanding** at **Sep 30, 2025:** **87,511,470**. ["87,511,470 shares issued and outstanding"](0001193125-25-274367|0) ### 4.2 Equity raises / financing history (as disclosed) In the 10‑K, Terns explicitly lists net proceeds from multiple offerings (IPO + subsequent offerings), and references **active at-the-market facilities**. ["received total net proceeds"](0000950170-25-042695|0) ["active at-the-market facilities"](0000950170-25-042695|0) **December 2025 major raise (8‑K Exhibit 1.1 + 8‑K Exhibit 99.1):** - Underwriting agreement covers **16,250,000** underwritten shares + **2,437,500** option shares. ["16,250,000 shares"](0001193125-25-315065|1) ["Option Shares: 2,437,500"](0001193125-25-315065|1) - The same underwriting agreement includes **public offering price per share: $40.00** in its pricing information section. ["Public Offering Price Per Share: $40.00"](0001193125-25-315065|1) - Exhibit 99.1 (Jan 2026) says the company completed an **upsized public offering of 18,687,500 shares** with **gross proceeds ~ $747.5M**. ["18,687,500 shares"](0001193125-26-008907|1) ["gross proceeds of approximately $747.5 million"](0001193125-26-008907|1) **Analyst-style implication:** This raise changes the narrative from “runway into 2028” to “runway into 2031” (per company’s own statement), and also raises the bar on clinical execution because dilution has already been “pulled forward” to secure the pivotal runway. ["runway into 2031"](0001193125-26-008907|1) --- ## 5) Governance & incentives (Proxy statement signals) From the 2025 proxy (DEF 14A), the **named executive officers for fiscal 2024** were: Amy Burroughs (CEO), Erin Quirk (former President/Head of R&D; served as PEO Aug 2023–Feb 2024), Mark Vignola (former CFO), and Melita Sun Jung (CBO). ["named executive officers for fiscal year 2024"](0000950170-25-060138|0) ### 5.1 Executive compensation snapshot (from the Summary Compensation Table) (Amounts shown are USD; table is straight from the proxy, not normalized.) | Named executive | Year | Total compensation | |---|---:|---:| | Amy Burroughs (CEO) | 2024 | $8,240,502 ["8,240,502"](0000950170-25-060138|0) | | Erin Quirk (former President/Head of R&D) | 2024 | $1,934,963 ["1,934,963"](0000950170-25-060138|0) | | Mark Vignola (former CFO) | 2024 | $2,916,937 ["2,916,937"](0000950170-25-060138|0) | | Melita Sun Jung (CBO) | 2024 | $2,196,084 ["2,196,084"](0000950170-25-060138|0) | **What this can tell you (interactive lens):** - If you’re assessing *alignment*, focus on the mix of equity vs cash and whether retention/severance items are recurring. The proxy explicitly discusses retention/separation-related payments for certain executives. ["separation agreement"](0000950170-25-060138|0) ["transition agreement"](0000950170-25-060138|0) --- ## 6) Risk radar (selected, filings-only) ### 6.1 China / cross-border operating & supply chain risk Terns’ 10‑K includes a dedicated “Risks Related to Doing Business in China” section, emphasizing trade policy uncertainty, potential restrictions involving Chinese CDMOs, and the possibility of disruption and increased costs. ["Risks Related to Doing Business in China"](0000950170-25-042695|0) ["tariffs and export control restrictions"](0000950170-25-042695|0) It specifically references proposed U.S. legislation and scrutiny related to certain Chinese biotech companies, and notes that escalation could hinder reliance on China-based service providers. ["proposed legislation"](0000950170-25-042695|0) ["retaliatory restrictions"](0000950170-25-042695|0) ### 6.2 Clinical, regulatory, and manufacturing execution risks (general biotech but explicitly disclosed) The 10‑K highlights that: - Clinical development is lengthy/expensive with uncertain outcomes. ["lengthy and expensive process"](0000950170-25-042695|0) - The company relies on third parties for manufacturing clinical supplies and expects to rely on third parties for commercial supply. ["rely completely on third parties to manufacture"](0000950170-25-042695|0) --- # Bottom line (filings-grounded synthesis) **TERN is a clinical-stage company whose investment case is primarily a function of (1) TERN‑701’s path to pivotal execution and differentiation in CML, (2) burn-rate trajectory as trials scale, and (3) financing/dilution strategy—recently transformed by a large late‑2025 raise that management says extends runway into 2031.** ["goal for pivotal trials"](0001193125-26-008907|1) ["gross proceeds of approximately $747.5 million"](0001193125-26-008907|1) ["runway into 2031"](0001193125-26-008907|1) --- ## If you want to “interact” with this analysis (choose one) A) I can turn the above into a **quarter-by-quarter catalyst dashboard** (CML vs obesity) using only disclosed timelines and trial gates. ["Planned milestones include"](0001193125-26-008907|1) B) I can build a **runway sensitivity table** (e.g., burn up/down scenarios) anchored to reported operating cash use and disclosed runway statements. ["Net cash used in operating activities"](0000950170-25-042695|0) ["fund our planned operating expenses into 2028"](0000950170-25-042695|0) C) I can extract and summarize **the exact China risk section** into a structured “risk register” (risk → trigger → mitigation implied by disclosures). ["Risks Related to Doing Business in China"](0000950170-25-042695|0)

## Terns Pharmaceuticals (TERN) — filings-first deep dive (SEC disclosures) ### Quick navigation (pick your angle) 1) **What the company is (and what it’s becoming)** → *Business model & strategy* 2) **Pipeline + catalyst calendar** → *Programs, trials, what to watch* 3) **Financial runway & burn** → *Cash, cash flow, operating expense mix* 4) **Capital structure & dilution history** → *Offerings, share count, ATM capacity* 5) **Governance & incentives** → *Exec comp signals* 6) **Risk radar (filings-only)** → *China exposure, manufacturing, clinical/regulatory* --- ## 1) What Terns is (and what it’s becoming) Terns describes itself as a **clinical-stage biopharmaceutical company** with a **portfolio of small-molecule candidates** spanning **oncology and obesity**. ["clinical-stage biopharmaceutical company"](0000950170-25-042695|0) A key “tell” in recent disclosures is how management frames the company’s future: it emphasizes **no approved products** and **no product revenue**, with progress and valuation hinging on clinical execution and capital access. ["no products approved"](0000950170-25-042695|0) ["have not generated any revenue"](0000950170-25-042695|0) --- ## 2) Pipeline + catalysts (from the 10‑K and recent 8‑K exhibits) ### 2.1 Pipeline snapshot (as disclosed) The FY2024 10‑K explicitly calls out these as the “most advanced” internally discovered programs: **TERN‑701, TERN‑601, TERN‑501**, plus **TERN‑800 series** discovery efforts. ["most advanced product candidates"](0000950170-25-042695|0) **What each program is (company language):** - **TERN‑701 (CML):** oral, allosteric **BCR‑ABL** TKI targeting the **ABL myristoyl pocket**; Phase 1 CARDINAL discussed; further data expected **Q4 2025** (per 10‑K). ["TERN-701 is our proprietary, oral"](0000950170-25-042695|0) ["Additional safety and efficacy data"](0000950170-25-042695|0) - **TERN‑601 (obesity):** oral, once-daily **GLP‑1 receptor agonist**; Phase 2 **FALCON** initiated (first patient enrolled March 2025), **12-week data expected Q4 2025**. ["TERN-601 is our small-molecule GLP-1 receptor agonist"](0000950170-25-042695|0) ["12-week data are expected"](0000950170-25-042695|0) - **TERN‑501 (legacy metabolic):** **THR‑β agonist**; company says it decided to **limit spend for MASH** after Phase 2a DUET top-line data, and is evaluating other opportunities. ["limit spend"](0000950170-25-042695|0) ### 2.2 “Near-term” oncology narrative: 2026 milestones for TERN‑701 In the Jan 2026 8‑K Exhibit 99.1 (JPM conference update), Terns lays out a concrete milestone chain for **TERN‑701**: - **Pivotal dose selection** mid‑2026 ["Selection of pivotal dose"](0001193125-26-008907|1) - **End‑of‑Phase‑2 FDA interaction** mid‑2026 ["End of Phase 2"](0001193125-26-008907|1) - **Updated/expanded CARDINAL data** by **2H26** ["updated and expanded CARDINAL data"](0001193125-26-008907|1) - **Initiate first 2L+ pivotal trial** late 2026 / early 2027 ["initiation of 2L+ pivotal trial"](0001193125-26-008907|1) It also states **FDA Fast Track designation** for CML in **Q4 2025**. ["Fast Track designation"](0001193125-26-008907|1) ### 2.3 “Interactive” catalyst checklist (how to use this) If you’re tracking TERN as a catalyst-driven name, you can treat these as *gates*: **Gate A — Dose & regulatory alignment (mid‑2026)** - Dose selection and EOP2 meeting matter because they convert “promising Phase 1/2” into a pivotal path. ["Selection of pivotal dose"](0001193125-26-008907|1) ["End of Phase 2"](0001193125-26-008907|1) **Gate B — Data durability and line-of-therapy expansion (2H26)** - Updated/expanded CARDINAL data is the proof point for both efficacy durability and safety profile scaling. ["updated and expanded CARDINAL data"](0001193125-26-008907|1) **Gate C — Pivotal trial start (late 2026/early 2027)** - Initiation is where spend profile can step up (trial footprint, manufacturing, site ramp). ["Initiation of first pivotal trial"](0001193125-26-008907|1) --- ## 3) Financial runway & burn (grounded in 10‑K + latest 10‑Q pulled) ### 3.1 Balance sheet: liquidity position (FY2024 vs Q3’25) **Condensed balance sheet (USD millions; filings scale is thousands, rescaled)** | Metric | FY2024 (Dec 31, 2024) | Q3’25 (Sep 30, 2025) | |---|---:|---:| | Cash & cash equivalents | $161.439 ["Cash and cash equivalents"](0000950170-25-042695|0) | $150.698 ["Cash and cash equivalents"](0001193125-25-274367|0) | | Marketable securities | $196.725 ["Marketable securities"](0000950170-25-042695|0) | $144.937 ["Marketable securities"](0001193125-25-274367|0) | | Total assets | $363.929 ["Total assets"](0000950170-25-042695|0) | $301.651 ["Total assets"](0001193125-25-274367|0) | **Interpretation:** Between FY2024 and Q3’25, total liquidity (cash + marketable securities) decreased, consistent with a development-stage company funding R&D primarily from its cash stack. ["Net cash used in operating activities"](0001193125-25-274367|0) ### 3.2 Operating burn & expense structure **Cash burn proxy = net cash used in operating activities** | Period | Net cash used in operating activities (USD millions) | |---|---:| | FY2024 | $70.016 ["Net cash used in operating activities"](0000950170-25-042695|0) | | FY2023 | $67.390 ["Net cash used in operating activities"](0000950170-25-042695|0) | | 9M 2025 | $63.093 ["Net cash used in operating activities"](0001193125-25-274367|0) | | 9M 2024 | $55.432 ["Net cash used in operating activities"](0001193125-25-274367|0) | **Operating P&L (FY2024 vs FY2023; USD millions)** | Metric | FY2024 | FY2023 | |---|---:|---:| | R&D expense | $70.112 ["Research and development"](0000950170-25-042695|0) | $63.497 ["Research and development"](0000950170-25-042695|0) | | G&A expense | $31.759 ["General and administrative"](0000950170-25-042695|0) | $39.061 ["General and administrative"](0000950170-25-042695|0) | | Net loss | $(88.853) ["Net loss"](0000950170-25-042695|0) | $(90.210) ["Net loss"](0000950170-25-042695|0) | **What stands out:** - Terns’ cost base is dominated by **R&D**, as expected, but **G&A fell** year-over-year in FY2024, with the 10‑K attributing the decrease primarily to lower personnel-related expenses vs 2023 leadership transition costs. ["decrease in general and administrative"](0000950170-25-042695|0) - Despite large net losses, **interest income is meaningful** (a function of the cash/investment base). ["Interest income"](0000950170-25-042695|0) ### 3.3 Runway: management guidance vs observed burn Management states it expects **existing capital resources to fund planned operating expenses into 2028** (10‑K). ["fund our planned operating expenses into 2028"](0000950170-25-042695|0) Separately, the Jan 2026 8‑K Exhibit 99.1 gives a dramatically updated post-financing view: **year‑end 2025 unaudited cash, cash equivalents and marketable securities of ~ $1.0B**, runway **into 2031** (company expectation). ["approximately $1.0 billion"](0001193125-26-008907|1) ["runway into 2031"](0001193125-26-008907|1) **How to sanity-check (interactive prompt):** - If you assume FY2024 operating cash use of about **$70M/year** continues, $1.0B could theoretically last well beyond 2031; but pivotal oncology trials can change the burn slope materially. The filings themselves flag that operating plans may change and additional funding may be needed sooner depending on factors. ["operating plans may change"](0000950170-25-042695|0) --- ## 4) Capital structure & dilution: what the disclosures say ### 4.1 Share count anchor points (from financial statements) - Shares **issued and outstanding** at **Dec 31, 2024:** **87,126,583**. ["87,126,583 shares issued and outstanding"](0000950170-25-042695|0) - Shares **issued and outstanding** at **Sep 30, 2025:** **87,511,470**. ["87,511,470 shares issued and outstanding"](0001193125-25-274367|0) ### 4.2 Equity raises / financing history (as disclosed) In the 10‑K, Terns explicitly lists net proceeds from multiple offerings (IPO + subsequent offerings), and references **active at-the-market facilities**. ["received total net proceeds"](0000950170-25-042695|0) ["active at-the-market facilities"](0000950170-25-042695|0) **December 2025 major raise (8‑K Exhibit 1.1 + 8‑K Exhibit 99.1):** - Underwriting agreement covers **16,250,000** underwritten shares + **2,437,500** option shares. ["16,250,000 shares"](0001193125-25-315065|1) ["Option Shares: 2,437,500"](0001193125-25-315065|1) - The same underwriting agreement includes **public offering price per share: $40.00** in its pricing information section. ["Public Offering Price Per Share: $40.00"](0001193125-25-315065|1) - Exhibit 99.1 (Jan 2026) says the company completed an **upsized public offering of 18,687,500 shares** with **gross proceeds ~ $747.5M**. ["18,687,500 shares"](0001193125-26-008907|1) ["gross proceeds of approximately $747.5 million"](0001193125-26-008907|1) **Analyst-style implication:** This raise changes the narrative from “runway into 2028” to “runway into 2031” (per company’s own statement), and also raises the bar on clinical execution because dilution has already been “pulled forward” to secure the pivotal runway. ["runway into 2031"](0001193125-26-008907|1) --- ## 5) Governance & incentives (Proxy statement signals) From the 2025 proxy (DEF 14A), the **named executive officers for fiscal 2024** were: Amy Burroughs (CEO), Erin Quirk (former President/Head of R&D; served as PEO Aug 2023–Feb 2024), Mark Vignola (former CFO), and Melita Sun Jung (CBO). ["named executive officers for fiscal year 2024"](0000950170-25-060138|0) ### 5.1 Executive compensation snapshot (from the Summary Compensation Table) (Amounts shown are USD; table is straight from the proxy, not normalized.) | Named executive | Year | Total compensation | |---|---:|---:| | Amy Burroughs (CEO) | 2024 | $8,240,502 ["8,240,502"](0000950170-25-060138|0) | | Erin Quirk (former President/Head of R&D) | 2024 | $1,934,963 ["1,934,963"](0000950170-25-060138|0) | | Mark Vignola (former CFO) | 2024 | $2,916,937 ["2,916,937"](0000950170-25-060138|0) | | Melita Sun Jung (CBO) | 2024 | $2,196,084 ["2,196,084"](0000950170-25-060138|0) | **What this can tell you (interactive lens):** - If you’re assessing *alignment*, focus on the mix of equity vs cash and whether retention/severance items are recurring. The proxy explicitly discusses retention/separation-related payments for certain executives. ["separation agreement"](0000950170-25-060138|0) ["transition agreement"](0000950170-25-060138|0) --- ## 6) Risk radar (selected, filings-only) ### 6.1 China / cross-border operating & supply chain risk Terns’ 10‑K includes a dedicated “Risks Related to Doing Business in China” section, emphasizing trade policy uncertainty, potential restrictions involving Chinese CDMOs, and the possibility of disruption and increased costs. ["Risks Related to Doing Business in China"](0000950170-25-042695|0) ["tariffs and export control restrictions"](0000950170-25-042695|0) It specifically references proposed U.S. legislation and scrutiny related to certain Chinese biotech companies, and notes that escalation could hinder reliance on China-based service providers. ["proposed legislation"](0000950170-25-042695|0) ["retaliatory restrictions"](0000950170-25-042695|0) ### 6.2 Clinical, regulatory, and manufacturing execution risks (general biotech but explicitly disclosed) The 10‑K highlights that: - Clinical development is lengthy/expensive with uncertain outcomes. ["lengthy and expensive process"](0000950170-25-042695|0) - The company relies on third parties for manufacturing clinical supplies and expects to rely on third parties for commercial supply. ["rely completely on third parties to manufacture"](0000950170-25-042695|0) --- # Bottom line (filings-grounded synthesis) **TERN is a clinical-stage company whose investment case is primarily a function of (1) TERN‑701’s path to pivotal execution and differentiation in CML, (2) burn-rate trajectory as trials scale, and (3) financing/dilution strategy—recently transformed by a large late‑2025 raise that management says extends runway into 2031.** ["goal for pivotal trials"](0001193125-26-008907|1) ["gross proceeds of approximately $747.5 million"](0001193125-26-008907|1) ["runway into 2031"](0001193125-26-008907|1) --- ## If you want to “interact” with this analysis (choose one) A) I can turn the above into a **quarter-by-quarter catalyst dashboard** (CML vs obesity) using only disclosed timelines and trial gates. ["Planned milestones include"](0001193125-26-008907|1) B) I can build a **runway sensitivity table** (e.g., burn up/down scenarios) anchored to reported operating cash use and disclosed runway statements. ["Net cash used in operating activities"](0000950170-25-042695|0) ["fund our planned operating expenses into 2028"](0000950170-25-042695|0) C) I can extract and summarize **the exact China risk section** into a structured “risk register” (risk → trigger → mitigation implied by disclosures). ["Risks Related to Doing Business in China"](0000950170-25-042695|0)